Merrimack completes enrollment for phase 2 trial of MM-093 in patients with psoriasis

By E. Janene Geiss

Philadelphia, April 19 - Merrimack Pharmaceuticals, Inc. announced Wednesday the completion of enrollment of 27 patients in a phase 2a study of the safety and efficacy of its immunomodulator, MM-093, in patients suffering from psoriasis.

MM-093, Merrimack's lead product, is a recombinant version of human alpha-fetoprotein, according to a company news release.

This study is a double-blind, placebo-controlled, randomized, outpatient clinical investigation in adult patients with moderate to severe chronic plaque psoriasis.

Each patient receives double-blind treatment for 12 weeks with a follow-up period of six weeks after the last dose. The study is being conducted at the University of Utah in Salt Lake City with Dr. Gerald Krueger as the principal investigator and at the Texas Dermatology Research Institute in Dallas, Texas with Dr. Alan Menter as the principal investigator.

Results from this pilot study will be available in late summer of this year, officials said.

The development of MM-093 is focused on diseases such as rheumatoid arthritis, psoriasis, and multiple sclerosis - indications for which published and proprietary pre-clinical data provide a compelling rationale for its use, officials said.

Merrimack is a Cambridge, Mass., privately held biotechnology company focused on the discovery and development of novel treatments for diseases in the areas of autoimmune disease and cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.